0JV.F Stock Analysis
0J
Uncovered
Ibio Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. The company is headquartered in New York City, New York and currently employs 105 full-time employees. The company went IPO on 2008-08-18. The firm is focusing its technologies on the research and development of novel products at its Drug Discovery Center in California. The firm through its FastPharming Manufacturing System and GlycaneeringSM Technologies develop its portfolio of proprietary biologic drug candidates. The firm operates through two segments: Biopharmaceuticals, and Bioprocessing. Its Biopharmaceuticals segment is engaged in large molecule discovery, development, and licensing activities. Its Bioprocessing segment is engaged in contract development and manufacturing services for recombinant proteins. Its pipeline includes IBIO-100, IBIO-101, IBIO-202, and IBIO-400. Its subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with GlycaneeringSM Development Services.